Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

Pfizer

Status and phase

Completed

Phase 4

Conditions

Hospital-Acquired Pneumonia

Treatments

Drug: Zavicefta, Ceftazidime-Avibactam

Study type

Interventional

Funder types

Industry

Identifiers

NCT04774094

C3591026

Details and patient eligibility

About

This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI in the hospital for at least 7 full days. There are no formal hypothesis tests planned for this study. The number and percent of participants having clinical cure, failure, and indeterminate at TOC visit in the cMITT analysis population will be summarized.

Enrollment

235 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female participants ≥18 and ≤90 years of age.
Onset of symptoms ≥48 hours after admission or <7 days after discharge from an inpatient acute or chronic care facility.
New or worsening infiltrate on chest X-ray obtained within 48 hours prior to screening.
Participants have systemic signs and respiratory signs or symptoms of HAP/VAP

Exclusion criteria

Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Participant is expected to require a treatment course for HAP longer than 14 days.
The total duration of antibiotic exposure for antibiotics whose administration begins in the 48 hours is longer than 24 hours.
Previous administration with an investigational drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
Acute Physiology and Chronic Health Evaluation (APACHE) II score >30 or <10 using the most recent available data.